Business description: AstraZeneca PLC

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (4.4%).

Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Number of employees: 89,900

Sales by Activity: AstraZeneca PLC

Fiscal Period: December20192020202120222023

Biopharmaceuticals

24.38B 26.62B 37.42B 44.35B 45.81B
See all business segments

Geographical breakdown of sales: AstraZeneca PLC

Fiscal Period: December20192020202120222023

United States

8.05B 8.96B 12.05B 17.28B 18.12B

China

4.87B 5.34B 6B 5.74B 5.87B

Japan

2.52B 2.57B 3.4B 3.99B 3.64B

United Kingdom

1.82B 1.74B 3.24B 3.12B 3.37B

Other Rest of Europe

1.29B 1.39B 1.95B 2.71B 3.11B

Germany

704M 937M 1.49B 1.9B 2.1B

Other Asia, Africa & Australasia

1.42B 1.53B 2.38B 2.41B 2.04B

Sweden

834M 1.03B 2.32B 1.72B 1.7B

Other Americas

814M 761M 1.2B 1.18B 1.68B

France

578M 653M 915M 1.11B 1.15B

Canada

466M 596M 772M 1.17B 967M

Spain

359M 398M 578M 738M 847M

Italy

396M 431M 577M 735M 813M

Australia

266M 282M 547M 571M 390M
See all geographic segments

Managers: AstraZeneca PLC

Director TitleAgeSince
Chief Executive Officer 64 30/09/2012
Director of Finance/CFO 50 31/07/2021
Chief Tech/Sci/R&D Officer 56 31/12/2019
Chief Tech/Sci/R&D Officer - 31/07/2023
Chief Tech/Sci/R&D Officer - 17/05/2023
See ASTRAZENECA PLC governance

Members of the board: AstraZeneca PLC

Manager TitleAgeSince
Director/Board Member 68 05/04/1999
Director/Board Member 64 30/09/2012
Director/Board Member 63 26/04/2017
Director/Board Member - 31/05/2017
Director/Board Member 66 30/09/2017
Director/Board Member 64 30/11/2017
Director/Board Member 63 31/12/2018
Chairman 68 26/04/2023
Director/Board Member - 30/09/2020
Director/Board Member - 31/10/2020
Composition of the Board of Directors

Shareholders: AstraZeneca PLC

NameEquities%Valuation
BlackRock Investment Management (UK) Ltd.
4.419 %
68,512,693 4.419 % 9 241 M p
Wellington Management Co. LLP
4.201 %
65,120,892 4.201 % 8 784 M p
The Vanguard Group, Inc.
3.661 %
56,762,000 3.661 % 7 656 M p
Investor AB (Investment Company)
3.328 %
51,587,810 3.328 % 6 958 M p
Norges Bank Investment Management
2.071 %
32,107,000 2.071 % 4 331 M p
NameEquities%Valuation
T. Rowe Price International Ltd.
2.028 %
62,892,582 2.028 % 4 253 M p
PRIMECAP Management Co.
1.354 %
41,980,045 1.354 % 2 839 M p
Wellington Trust Co., NA
1.201 %
37,247,083 1.201 % 2 519 M p
Capital Research & Management Co. (International Investors)
1.188 %
36,821,151 1.188 % 2 490 M p
Fidelity Management & Research Co. LLC
0.7453 %
23,110,253 0.7453 % 1 563 M p
NameEquities%Valuation
Caixa DTVM SA
0.002876 %
267,643 0.002876 % 3 M p
List of ASTRAZENECA PLC shareholders

Holdings: AstraZeneca PLC

NameEquities%Valuation
18,750,00075.00%1,456,152,000 $
35,043,6249.84%970,540,876 $
66,093,10816.61%52,924,717 $
16,000,00015.98%32,615,520 $
7,485,5009.25%11,258,417 $
387,3297.34%8,726,522 $
9,504,4658.14%1,016,978 $

Company details: AstraZeneca PLC

AstraZeneca PLC

Cambridge Biomedical Campus 1 Francis Crick Avenue

CB2 0AA, Cambridge

+44 20 3749 5000

http://www.astrazeneca.co.uk
address AstraZeneca PLC(AZN)

Group companies: AstraZeneca PLC

NameCategory and Sector
Astrazeneca Treasury BV
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Alexion Pharmaceuticals, Inc. /New/
See all subsidiaries

Other Pharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+0.25%+0.55%+4.38%+28.62%208B
-0.44%-4.07%+36.30%+226.05%720B
+1.00%+1.32%+18.10%+110.47%488B
-1.74%-2.55%-5.43%-11.39%359B
-0.74%-1.18%+15.29%+38.97%310B
-1.24%-1.60%-4.43%+37.36%255B
+0.83%+0.87%+0.63%-32.12%231B
-0.92%-2.40%+2.76%+17.79%201B
-0.85%-1.74%+0.47%+29.65%148B
-1.33%0.00%-11.91%-52.20%145B
Average -0.10%-1.46%+5.62%+39.32% 306.61B
Weighted average by Cap. -0.05%-1.83%+11.93%+76.03%
See all sector performances
Trading Rating
Investor Rating
ESG Refinitiv
B+
surperformance-ratings-light-chart ASTRAZENECA-PLCMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
134.34USD
Average target price
177.04USD
Spread / Average Target
+31.79%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Company AstraZeneca PLC